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We describe here the case of a 39-year-old woman with a cortisol-producing adrenal adenoma and she presented 
with  endometrial  hyperplasia  and  hypertension  without  the  specific  characteristics  of  Cushing's  syndrome.  The  patient 
had consulted a gynecologist for menometrorrhagia 2 years prior to her referral and she was diagnosed with endometrial 
hyperplasia  and  hypertension.  Her  blood  pressure  and  the  endometrial  lesion  were  refractory  despite  taking  multiple 
antihypertensives  and  repetitive  dilation  and  curettage  and  progestin  treatment.  On  admission,  the  clinical  examination 
revealed  mild  central  obesity  (a  body  mass  index  of  22.9  kg/m
2,  a  waist  circumference  of  85  cm  and  a  hip 
circumference of 94cm), but there was no hirsutism and myopathy. She showed impaired glucose tolerance on an oral 
glucose tolerance test. The biochemical hypercortisolemia together with the prolactin and androgen levels were evaluated 
to explore the cause of her anovulation. Adrenal Cushing's syndrome was confirmed on the basis of the elevated urinary 
free cortisol (454 μg/24h, normal range: 20-70) with a suppressed ACTH level (2.0 pg/mL, normal range: 6.0-76.0) and 
the  loss  of  circadian  cortisol  secretion.  A  CT  scan  revealed  a  3.1  cm,  hyperechoic,  well-marginated  mass  in  the  left 
adrenal gland. Ten months post-adrenalectomy, the patient had unintentionally lost 9 kg of body weight, had regained 
a  regular  menstrual  cycle  and  had  normal  thickness  of  her  endometrium.
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INTRODUCTION
The  prevalence of  obesity  and  its related  disorders  is  rapidly 
increasing  with  increasing  economic  development  and  the 
growing convenience of modern life, but obesity and weight gain 
can  also  be  caused  by  drugs  and  several  endocrine  disorders 
such  as  Cushing's  syndrome.  Cases  of  mild  or  subclinical 
Cushing's  syndrome  are  increasingly  being  reported  owing  to 
emerging  concerns  about  health  problems  and  the  develop-
ments  of  image  technology
1).  Cushing's  syndrome  is  well 
characterized  by  central  obesity,  proximal  muscle  weakness, 
bruising,  violet  striae,  menstrual  irregularities  and  hirsuitism. 
Obesity,  especially  central  obesity,  is  also  associated  with 
metabolic  syndrome,  polycystic  ovary  syndrome  (PCOS)  and 
other  disorders  that  present  with  menstrual  irregularities, 
including  endometrial  hyperplasia.  Clinicians  must  stay  alert  for 
the possibility of secondary causes of menstrual abnormalities in 
patients with recent weight gain to formulate a correct diagnosis.
In this report, we describe the case of a 39-year-old woman 
with  a  cortisol-producing  adrenal  adenoma  that  presented  as 
refractory  endometrial  hyperplasia  and  hypertension,  and  she 
was  without  any  of  the  remarkable,  specific  characteristics  of 
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Figure  1.  There  is  no  obvious  Cushingoid  features  such  as  hirsuitism, 
acne  or  a  moon  face.
Figure  2.  An  adrenal  CT  scan  of  patient  shows  a  3.1-cm  sized 
well-marginated  mass  in  the  left  adrenal  gland  (arrows).
CASE REPORT
A  39-year-old  woman  had  been  previously  diagnosed  with 
endometrial hyperplasia and hypertension, and she was referred 
to  our  department  for  further  evaluation  and  management  of 
persistent menometrorrhagia despite being treated with progestin 
and ten dilatation and curettage procedures in 2 years. Her past 
medical  history  was  negative  for  diabetes  mellitus,  but  positive 
for  hypertension.  She  had  been  treated  with  antihypertensive 
medication for 2 years, but her blood pressure control was not 
satisfactory.  The  patient  had  gained  7  kg  in  body  weight  over 
the past 4 years. The patient had delivered two children vaginally 
without complication, at the ages of 25 and 28, respectively, and 
she  had  a  negative  history  of  spontaneous  or elective  abortion. 
She  was  a  former  nurse  and  denied  using  alcohol.
A t  t h e  t i m e  o f  h e r  r e f e r r a l ,  h e r  b l o o d  p r e s s u r e  w a s  1 5 5 / 9 2  
mmHg.  She  presented  with  mild  central  obesity  (waist  to  hip 
ratio,  0.90);  her  weight  was  60  kg,  and  her  BMI  was  22.9 
kg/m
2.  No  violet  striae,  proximal  myopathy,  hirsutism  or  acne 
were  observed,  but  minor  bruising  was  present  on  her  forearm 
(Figure  1).
Her  hormone  levels  during  the  early  follicular  phase,  which 
had  been  determined  2  years  earlier  upon  a  previous  visit  to  a 
local  clinic  for  abnormal  uterine  bleeding  prior  to  her  referral, 
w e r e  L H :  3 . 2  m I U / m L  ( n o r m a l  r a n g e :  2 . 0 - 1 5 . 0  m I U / m L ) ,  F S H :  
6.6  mIU/mL  (3.0-20.0  mIU/mL),  estrone  (E1):  15.0  pg/mL 
( 1 . 5 - 1 5 . 0  p g / m L )  a n d  e s t r a d i o l  ( E 2 ) :  6 . 3  p g / m L  ( 2 0 . 0 - 1 4 5 . 0  
pg/mL).  However,  her  progesterone  level  was  very  low  at  0.2 
ng/mL  (3.0-20.0  ng/mL),  suggesting  chronic  anovulation  and 
dysfunctional  uterine  bleeding.  At  that  time,  the  results  of  a 
thyroid  function  test,  a  prolactin  level  test,  a  liver  function t e s t  
and  the  platelet  count  were  all  within  normal  ranges. 
Other  biochemical  laboratory  tests  gave  the  following  results: 
p r o t e i n ,  7 . 1  g / d L  ( 6 . 0 - 8 . 1  g / d L ) ,  a l b u m i n :  4 . 2  g / d L  ( 3 . 2 - 5 . 3  
g/dL), cholesterol: 149 mg/dL (120-220 mg/dL), LDL-cholesterol: 
100  mg/dL  (0-130  mg/dL),  HDL-cholesterol:  45mg/dL  (35-80 
mg/dL),  triglyceride:  79  mg/dL  (35-200  mg/dL),  alkaline 
phosphatase:  66  IU/L  (39-120  IU/L)  and  creatinine:  0.9  mg/dL 
(0.5-1.1  mg/dL).  An  oral  glucose  tolerance  test  indicated 
impaired glucose tolerance (fasting glucose: 74 mg/dL, 2-h: 187 
mg/dL).
Ultrasonography  showed  a  15.6  mm  thickness  of  the 
endometrium.  Endometrial  biopsy  revealed  simple  endometrial 
hyperplasia  without  atypia.  Ultrasonography  revealed  a  2.5  cm 
size simple cyst on the left ovary; otherwise, the architecture of 
b o t h  o v a r i e s  w a s  n o r m a l .
Although  she  did  not  present  with  the  typical  features  of 
Cushing's syndrome, we ordered laboratory tests for cortisol and 
ACTH  as  well  as  the  sex  hormone,  gonadotropin  and  prolactin 
levels to investigate the cause of her chronic anovulation and the 
persistent menstrual irregularity. The results were 24-h urine free 
cortisol:  454.5  μg/24h  (20.0-70.0  μg/24h),  serum  ACTH:  2.0 
pg/dL  (6.0-76.0  pg/dL)  and  midnight  serum  cortisol:  15.3  g/dL 
(0-10.0 μg/dL); this all suggested hypercortisolemia and loss of 
the  circadian  rhythm.  The  24-h  urine  free  estrone  and  free 
estradiol  levels  were  3.3  g/24h  (2.0-39.0  μg/24h)  and  1.9  μ
g/24h  (1.0-23.0  μg/24h),  respectively.  The  E1/E2  ratio  was 
elevated in the serum and urine (2.4 and 1.7, respectively). The 
serum  testosterone  was  below  the  detectable  range  of  0.10 
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marginated  mass  in  the  left  adrenal  gland  (Figure  2).
The  patient  was  diagnosed  as  a  cortisol-producing  adrenal 
adenoma  and  she  underwent  a  left  adrenalectomy.  During  the 
1 0 - m o n t h s  f o l l o w - u p ,  h e r  h o r m o n a l  l a b o r a t o r y  t e s t s  w e r e  2 4 - h  
urine free cortisol: 45.9 μg/24h, serum ACTH: 61.9 pg/dL and 
serum  cortisol:  15.3  μg/dL.  The  serum  estrone  and  estradiol 
levels were 38.00 pg/mL and 40.45 pg/mL, respectively, and the 
24-h urine free estrone and free estradiol levels were 2.0 μg/24h 
and  1.1  μg/24h,  respectively.  The  E1/E2  ratios  in  the  serum 
and  the  24-hour  urine  were  0.9  and  1.8,  respectively.  She 
showed a gradual and unintentional loss of 9 kg of body weight. 
Her waist to hip ratio was decreased from 0.90 to 0.78, and she 
regained  regular menstrual cycles. Her blood pressure was well 
controlled  by  a  half  dose  of  the  previous  medication  after 
adrenalectomy.  Endometrial  hyperplasia,  as  determined  by 
ultrasonography,  was  not  seen  thereafter. 
DISCUSSION
The patient in this case was referred to us for the evaluation 
of the recurrent endometrial hyperplasia that was not resolved by 
r e p e a t e d  t h e r a p e u t i c  c u r e t t a g e  a n d  p r o g e s t i n  t r e a t m e n t  f o r  2  
years,  and  she  was  finally  diagnosed  with  a  cortisol-producing 
adenoma.  After  left  adrenalectomy,  her  uterine  lesion  and 
menstrual abnormality completely resolved, and she experienced 
unintentional  weight  loss.  Patients  with  Cushing's  syndrome 
almost always show insulin resistance that's attributable to chronic 
hypercortisolism,  which  is  frequently  accompanied  by  metabolic 
syndrome and PCOS, and rarely by endometrial hyperplasia
2). It 
i s  known t hat  PCOS and anovul at or y cycl es  can be caus ed by 
insulin  resistance.  In  addition,  it  has  been  suggested  that 
menstrual  irregularity  might  result  from  hypercortisolemic 
inhibition  of  gonadotrophin  release  at  the  hypothalamic  level 
rather  than  being  caused  by  elevated  levels  of  circulating 
androgen
3, 4).  It  was  proposed  that  hypercortisolemia  could 
suppress  pulsatile  LH  secretion  by  inhibiting  pituitary  respon-
siveness  to  gonadotropin-releasing  hormone  (GnRH)
5).  However, 
the mechanisms of the occurrence of endometrial hyperplasia in 
these  patients  are  poorly  understood,  and  to  the  best  of  our 
knowledge,  there  are  no  other  cases  in  the  literature  of 
Cushing's  syndrome  presenting  as  endometrial  hyperplasia. 
A l t h o u g h  o u r  p a t i e n t  p r e s e n t e d  w i t h  m e t a b o l i c  s y n d r o m e  a n d  
minor  bruising,  these  signs  were  not  accompanied  by  any 
obvious  clinical  features  of  Cushing's  syndrome.
Although  we  confirmed  chronic  anovulation  and  Cushing's 
syndrome  in  this  patient,  an  inappropriately  low  level  of  serum 
estradiol  had  been  found  by  a  local  clinic  2  years  prior  to  her 
referral,  suggesting  hypogonadotrophic  hypogonadism  as  the 
cause of her menstrual disturbance, which was in contrast to the 
elevated  LH  levels  that  are  usually  observed  in  patients  with 
PCOS.  Continuously  elevated  cortisol  inhibits  the  activity  of  17 
beta-hydroxysteroid  dehydrogenase  and  it  might  prohibit  the 
action of progesterone in the uterus as well as the secretion of 
GnRH  from  the  thalamus
6).  In  this  patient,  these  hormonal 
changes  finally  resulted  in  a  functional  and  absolute  pro-
gesterone  deficiency  and  recurrent  endometrial  hyperplasia, 
irrespective  of  repetitive  curettage  and  progestin  treatment.
Given that the cortisol receptor has not been demonstrated in 
the  uterine  stromal  or  endometrial  cells,  the  possibility  seems 
remote  that  chronic  excess  cortisol  alone  induced  the 
endometrial  hyperplasia.  Rather,  based  on  the  fact  that  both 
insulin  receptors  and  IGF-1  receptors  are  expressed  in 
endometrial  cells
7, 8),  we  suggest  that  the  hyperinsulinemia 
induced  by  excess  cortisol  in  this  patient  could  have  been  an 
additive factor for the development of endometrial hyperplasia. It 
has been suggested that insulin resistance or hyperinsulinemia in 
patients  with  PCOS  increases  the  production  of  androgens  in 
the  theca  cells  and  this  augments  aromatase  activity  in 
adipocytes, thereby increasing the conversion to estrone and the 
LH level. Our patient showed an elevated E1/E2 ratio in both the 
serum and urine (2.4 and 1.7, respectively), indicating increased 
production  of  estrone  in  the  peripheral  tissues.  In  contrast,  the 
androgen  and  LH  determinations  in  her  serum  revealed  a  low 
estrogen  level  that  was  attributable  to  the  inhibitory  effects  of 
hypercortisolemia  on  the  thalamus  and  ovaries.
Our  patient  presented  with  chronic  anovulation  and 
endometrial  hyperplasia,  and  she  was  found  to  have  Cushing's 
syndrome;  she  experienced  complete  resolution  of  her  uterine 
lesion  and  cardiometabolic  abnormalities  after  removal  of  a  left 
adrenal  tumor.  This  case  demonstrates  the  necessity  of 
performing  endocrine  tests,  including  urinary  free  cortisol 
measurements,  in  young  women  with  endometrial  hyperplasia 
and  anovulation  even  when  these  patients  do  not  show  the 
typical  features  of  Cushing's  syndrome. 
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